
    
      This is a prospective, randomized, 1:1 balanced, controlled, double-blind, multi-center study
      comparing clinical outcomes at 12 months between MT005 (MiStent) and XIENCE in an all-comers
      population, including patients with symptomatic coronary artery disease including patients
      with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for
      percutaneous coronary interventions.
    
  